Symbols / AUTL Stock $1.60 +1.27% Autolus Therapeutics plc

Healthcare • Biotechnology • United Kingdom • NMS
AUTL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Christian Martin Itin Ph.D.
Exch · Country NMS · United Kingdom
Market Cap 425.83M
Enterprise Value -154.46M
Income -53.28M
Sales 1.08M
FCF (ttm) —
Book/sh 5.91
Cash/sh 5.52
Employees 752
Insider 10d —
IPO Jun 22, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.27
PEG —
P/S 394.83
P/B 0.27
P/C —
EV/EBITDA 2.24
EV/Sales -143.22
Quick Ratio 10.32
Current Ratio 11.05
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.08
EPS next Y -0.71
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-27
ROA -22.27%
ROE -29.62%
ROIC —
Gross Margin 0.00%
Oper. Margin -65.71%
Profit Margin 0.00%
Shs Outstand 266.14M
Shs Float 33.90M
Insider Own 18.08%
Instit Own 77.38%
Short Float 7.58%
Short Ratio 9.12
Short Interest 13.09M
52W High 2.70
vs 52W High -40.74%
52W Low 1.18
vs 52W Low 36.17%
Beta —
Impl. Vol. 25.00%
Rel Volume 0.67
Avg Volume 1.62M
Volume 1.09M
Target (mean) $8.68
Tgt Median $9.00
Tgt Low $5.00
Tgt High $11.00
# Analysts 9
Recom Strong_buy
Prev Close $1.58
Price $1.60
Change 1.27%
About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.68
Mean price target
2. Current target
$1.60
Latest analyst target
3. DCF / Fair value
$8.68
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$1.60
Low
$5.00
High
$11.00
Mean
$8.68

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-09 reit Needham Buy → Buy $10
2026-03-31 main Mizuho Outperform → Outperform $10
2026-03-27 reit Needham Buy → Buy $10
2026-02-17 init HC Wainwright & Co. — → Buy $9
2026-01-12 main Needham Buy → Buy $10
2025-12-29 main Needham Buy → Buy $11
2025-12-12 reit Needham Buy → Buy $10
2025-11-03 reit Needham Buy → Buy $10
2025-10-20 reit Needham Buy → Buy $10
2025-08-13 main Wells Fargo Overweight → Overweight $5
2025-07-21 reit Needham Buy → Buy $10
2025-06-12 reit Needham Buy → Buy $10
2025-04-10 reit Needham Buy → Buy $10
2025-04-01 main Truist Securities Buy → Buy $10
2025-03-21 main Wells Fargo Overweight → Overweight $6
2025-01-13 reit Needham Buy → Buy $10
2024-12-09 reit Needham Buy → Buy $10
2024-12-05 reit Needham Buy → Buy $10
2024-11-18 up Goldman Sachs Neutral → Buy $8
2024-11-15 up Redburn Atlantic Neutral → Buy $13
News
RSS: Latest AUTL news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
75.39
+644.94%
10.12
+496.00%
1.70
-72.59%
6.19
Operating Revenue
75.39
+644.94%
10.12
+496.00%
1.70
-72.59%
6.19
Cost Of Revenue
96.37
+746.31%
11.39
0.00
—
Reconciled Cost Of Revenue
96.37
+746.31%
11.39
0.00
—
Gross Profit
-20.98
-1555.96%
-1.27
-174.62%
1.70
—
Operating Expense
249.56
+3.92%
240.16
+35.51%
177.23
+18.87%
149.09
Research And Development
117.69
-14.99%
138.44
+6.10%
130.48
+11.19%
117.35
Selling General And Administration
131.87
+29.64%
101.72
+117.61%
46.74
+46.54%
31.90
General And Administrative Expense
—
—
46.74
+46.54%
31.90
Other Gand A
—
—
46.74
+46.54%
31.90
Other Operating Expenses
—
—
—
-0.17
Total Expenses
345.93
+37.52%
251.55
+41.94%
177.23
+18.87%
149.09
Operating Income
-270.54
-12.06%
-241.43
-37.54%
-175.53
-22.84%
-142.89
Total Operating Income As Reported
-270.54
-12.06%
-241.43
-34.35%
-179.70
—
EBITDA
-239.07
-18.28%
-202.12
-28.93%
-156.77
-18.55%
-132.24
Normalized EBITDA
-241.24
-19.94%
-201.13
-29.57%
-155.24
-17.85%
-131.72
Reconciled Depreciation
9.81
+27.19%
7.72
+17.53%
6.57
-11.55%
7.42
EBIT
-248.89
-18.61%
-209.84
-28.47%
-163.34
-16.95%
-139.66
Total Unusual Items
2.16
+318.71%
-0.99
+35.53%
-1.53
-197.86%
-0.52
Total Unusual Items Excluding Goodwill
2.16
+318.71%
-0.99
+35.53%
-1.53
-197.86%
-0.52
Special Income Charges
—
-0.64
+84.74%
-4.17
-710.29%
-0.52
Impairment Of Capital Assets
—
0.41
+8.38%
0.38
0.00
Net Income
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Pretax Income
-285.56
-30.31%
-219.13
-5.15%
-208.40
-40.27%
-148.57
Net Non Operating Interest Income Expense
-17.69
-176.71%
23.06
+173.07%
-31.56
-338.54%
-7.20
Interest Expense Non Operating
36.67
+294.56%
9.29
-79.38%
45.07
+406.09%
8.90
Net Interest Income
-17.69
-176.71%
23.06
+173.07%
-31.56
-338.54%
-7.20
Interest Expense
36.67
+294.56%
9.29
-79.38%
45.07
+406.09%
8.90
Interest Income Non Operating
18.98
-41.34%
32.35
+139.58%
13.51
+690.69%
1.71
Interest Income
18.98
-41.34%
32.35
+139.58%
13.51
+690.69%
1.71
Other Income Expense
2.68
+448.24%
-0.77
+41.39%
-1.31
-186.15%
1.52
Other Non Operating Income Expenses
0.52
+134.09%
0.22
-0.90%
0.22
-89.11%
2.04
Gain On Sale Of Security
2.16
+318.71%
-0.99
-137.48%
2.64
—
Tax Provision
1.97
+29.06%
1.53
+8142.11%
-0.02
-106.99%
0.27
Tax Rate For Calcs
0.00
+0.00%
0.00
+230669.23%
0.00
-99.96%
0.00
Tax Effect Of Unusual Items
0.45
+318.71%
-0.21
-148404.12%
-0.00
+99.87%
-0.11
Net Income Including Noncontrolling Interests
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Net Income From Continuing Operation Net Minority Interest
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Net Income From Continuing And Discontinued Operation
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Net Income Continuous Operations
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Normalized Income
-289.24
-31.54%
-219.88
-6.30%
-206.85
-39.36%
-148.43
Net Income Common Stockholders
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Diluted EPS
-1.08
-25.58%
-0.86
+28.33%
-1.20
+23.57%
-1.57
Basic EPS
-1.08
-25.58%
-0.86
+28.33%
-1.20
+23.57%
-1.57
Basic Average Shares
266.14
+4.30%
255.16
+46.69%
173.94
+83.11%
94.99
Diluted Average Shares
266.14
+4.30%
255.16
+46.69%
173.94
+83.11%
94.99
Diluted NI Availto Com Stockholders
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Gain On Sale Of PPE
—
-0.22
+94.12%
-3.79
-636.12%
-0.52
Line Item Trend 2023-12-31
Total Assets
375.38
Current Assets
275.30
Cash Cash Equivalents And Short Term Investments
239.57
Cash And Cash Equivalents
239.57
Cash Financial
—
Other Short Term Investments
0.00
Receivables
24.54
Accounts Receivable
0.11
Other Receivables
20.66
Taxes Receivable
2.77
Accrued Interest Receivable
1.00
Inventory
0.00
Raw Materials
0.00
Work In Process
0.00
Finished Goods
0.00
Prepaid Assets
8.64
Current Deferred Assets
1.79
Restricted Cash
0.77
Other Current Assets
—
Total Non Current Assets
100.08
Net PPE
95.65
Gross PPE
124.43
Accumulated Depreciation
-28.77
Properties
0.00
Machinery Furniture Equipment
6.14
Construction In Progress
12.54
Other Properties
93.02
Leases
12.73
Goodwill And Other Intangible Assets
0.00
Other Intangible Assets
—
Non Current Deferred Assets
3.06
Non Current Deferred Taxes Assets
3.06
Non Current Prepaid Assets
0.98
Other Non Current Assets
0.38
Total Liabilities Net Minority Interest
263.91
Current Liabilities
44.74
Payables And Accrued Expenses
24.39
Payables
0.10
Accounts Payable
0.10
Current Accrued Expenses
24.29
Pensionand Other Post Retirement Benefit Plans Current
14.76
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
5.05
Current Capital Lease Obligation
5.05
Other Current Liabilities
0.53
Total Non Current Liabilities Net Minority Interest
219.17
Long Term Debt And Capital Lease Obligation
47.91
Long Term Capital Lease Obligation
47.91
Tradeand Other Payables Non Current
0.36
Other Non Current Liabilities
170.90
Stockholders Equity
111.47
Common Stock Equity
111.47
Capital Stock
0.01
Common Stock
0.01
Share Issued
174.10
Ordinary Shares Number
174.10
Treasury Shares Number
0.00
Additional Paid In Capital
1,018.90
Retained Earnings
-878.56
Gains Losses Not Affecting Retained Earnings
-28.99
Other Equity Adjustments
-28.99
Total Equity Gross Minority Interest
111.47
Total Capitalization
111.47
Working Capital
230.56
Invested Capital
111.47
Total Debt
52.97
Capital Lease Obligations
52.97
Net Tangible Assets
111.47
Tangible Book Value
111.47
Other Equity Interest
0.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-283.57
-37.47%
-206.27
-41.68%
-145.59
-29.63%
-112.31
Cash Flow From Continuing Operating Activities
-283.57
-37.47%
-206.27
-41.68%
-145.59
-29.63%
-112.31
Net Income From Continuing Operations
-287.53
-30.30%
-220.66
-5.89%
-208.38
-40.01%
-148.84
Depreciation Amortization Depletion
9.81
+27.19%
7.72
+17.53%
6.57
-11.55%
7.42
Depreciation
8.30
+9.82%
7.55
+15.06%
6.57
—
Amortization Cash Flow
1.52
+837.04%
0.16
0.00
—
Depreciation And Amortization
9.81
+27.19%
7.72
+17.53%
6.57
-11.55%
7.42
Amortization Of Intangibles
1.52
+837.04%
0.16
0.00
—
Other Non Cash Items
22.51
+79.95%
12.51
-74.55%
49.15
+299.09%
12.32
Stock Based Compensation
14.44
-6.68%
15.47
+38.09%
11.20
-6.74%
12.01
Asset Impairment Charge
12.63
+2950.24%
0.41
+8.38%
0.38
0.00
Deferred Tax
-0.29
-54.59%
-0.18
+81.24%
-0.99
-267.91%
-0.27
Deferred Income Tax
-0.29
-54.59%
-0.18
+81.24%
-0.99
-267.91%
-0.27
Operating Gains Losses
-3.15
-248.66%
2.12
+155.63%
-3.81
-184.53%
4.51
Net Foreign Currency Exchange Gain Loss
-3.17
-266.86%
1.90
+124.96%
-7.60
-290.29%
4.00
Gain Loss On Sale Of PPE
0.01
-93.72%
0.22
-94.12%
3.79
+636.12%
0.52
Change In Working Capital
-51.99
-119.78%
-23.66
-8201.03%
0.29
-45.52%
0.54
Change In Receivables
-24.16
0.00
—
—
Changes In Account Receivables
-24.16
0.00
—
—
Change In Inventory
-40.25
-851.76%
-4.23
0.00
—
Change In Prepaid Assets
-4.57
+85.99%
-32.58
-343.91%
13.36
+223.62%
-10.81
Change In Payables And Accrued Expense
2.34
-82.70%
13.52
+2665.64%
0.49
-96.95%
16.03
Change In Accrued Expense
1.04
-91.29%
11.93
+1095.79%
1.00
-93.77%
16.01
Change In Payable
1.30
-18.24%
1.59
+412.38%
-0.51
-2413.64%
0.02
Change In Account Payable
1.30
-18.24%
1.59
+412.38%
-0.51
-2413.64%
0.02
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
14.64
+4068.83%
-0.37
+97.28%
-13.55
-189.20%
-4.69
Investing Cash Flow
158.46
+140.16%
-394.55
-3491.41%
-10.99
-1.34%
-10.84
Cash Flow From Continuing Investing Activities
158.46
+140.16%
-394.55
-3491.41%
-10.99
-1.34%
-10.84
Net PPE Purchase And Sale
-19.04
+13.73%
-22.07
-100.94%
-10.99
-1.34%
-10.84
Purchase Of PPE
-19.04
+13.73%
-22.07
-100.94%
-10.99
-1.34%
-10.84
Capital Expenditure
-27.13
+22.08%
-34.82
-216.94%
-10.99
-1.34%
-10.84
Net Investment Purchase And Sale
185.59
+151.59%
-359.73
0.00
—
Purchase Of Investment
-242.62
+32.56%
-359.73
0.00
—
Sale Of Investment
428.21
0.00
—
—
Net Intangibles Purchase And Sale
-8.09
+36.53%
-12.74
0.00
—
Purchase Of Intangibles
-8.09
+36.53%
-12.74
0.00
—
Financing Cash Flow
-4.34
-100.74%
589.55
+66867.16%
-0.88
-100.39%
223.61
Cash Flow From Continuing Financing Activities
-4.34
-100.74%
589.55
+66867.16%
-0.88
-100.39%
223.61
Net Common Stock Issuance
0.00
-100.00%
549.98
0.00
-100.00%
163.85
Proceeds From Stock Option Exercised
0.00
-100.00%
0.60
+2129.63%
0.03
-76.92%
0.12
Net Other Financing Charges
-4.34
-111.13%
38.98
+4382.97%
-0.91
-101.53%
59.64
Changes In Cash
-129.45
-1048.72%
-11.27
+92.84%
-157.46
-256.73%
100.46
Effect Of Exchange Rate Changes
6.28
+2505.75%
-0.26
-101.74%
15.03
+152.97%
-28.38
Beginning Cash Position
228.81
-4.80%
240.34
-37.21%
382.76
+23.20%
310.68
End Cash Position
105.64
-53.83%
228.81
-4.80%
240.34
-37.21%
382.76
Free Cash Flow
-310.70
-28.87%
-241.09
-53.98%
-156.57
-27.14%
-123.15
Income Tax Paid Supplemental Data
1.97
-17.69%
2.39
+333.94%
0.55
+16.99%
0.47
Common Stock Issuance
0.00
-100.00%
549.98
0.00
-100.00%
163.85
Issuance Of Capital Stock
0.00
-100.00%
549.98
0.00
-100.00%
163.85
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category